Black participation in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial

被引:55
|
作者
Stallings, FL
Ford, ME
Simpson, NK
Fouad, M
Jernigan, JC
Trauth, JM
Miller, DS
机构
[1] NCI, Div Canc Prevent, Early Detect Res Grp, EPN 330, Bethesda, MD 20892 USA
[2] Ctr Dis Control & Prevent, Div Canc Prevent & Control, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA
[3] Henry Ford Hlth Syst, Ctr Med Treatment Effectiveness Programs Diverse, Detroit, MI USA
[4] Univ Alabama, Birmingham, AL USA
[5] Univ Pittsburgh, Grad Sch Publ Hlth, Pittsburgh, PA USA
来源
CONTROLLED CLINICAL TRIALS | 2000年 / 21卷 / 06期
关键词
screening; cancer; patient selection; minority groups;
D O I
10.1016/S0197-2456(00)00093-3
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
The primary goal of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial is to learn whether widespread use of screening tests to detect these cancers will reduce associated mortality. Blacks have the highest age-adjusted cancer incidence and mortality rates of any population group in the United States, but several barriers to their participation in clinical research such as the PLCO trial exist. These barriers involve sociocultural, economic, and individual factors, as well as factors inherent in trial designs. Population diversity in the PLCO trial is necessary to preserve scientific validity and generalizability of trial results. Therefore, the National Cancer Institute and the Centers for Disease Control and Prevention are collaborating to ensure adequate representation of blacks in the PLCO trial. For example, the agencies have funded several new activities designed to better understand and overcome barriers to participation in the trial. These activities include the African American Men Project, a randomized trial designed to evaluate the efficacy of three-increasingly intensive recruitment interventions in recruiting black men; the establishment of a minority-focused PLCO trial screening center, a study to identify factors that influenced the decisions of black women recruited to participate in the PLCO trial; and a study to examine the psychosocial factors that influence blacks' decision making to engage in cancer screening and participation in research similar to the PLCO trial. The results of these activities will allow for a more thorough examination of cancer-related issues of importance to blacks and will help shed light on factors that influence their decisions to participate in cancer screening and prevention clinical trials. Control Clin Trials 2000;21:379S-389S (C) Elsevier Science Inc. 2000.
引用
收藏
页码:379S / 389S
页数:11
相关论文
共 50 条
  • [31] SECOND CANCERS FOLLOWING RADIOTHERAPY IN PROSTATE CANCER PATIENTS IN THE PROSTATE, LUNG, COLORECTAL AND OVARIAN (PLCO) CANCER SCREENING TRIAL
    Black, Amanda
    Pinsky, Paul F.
    Grubb, Robert L.
    Daugherty, Sarah E.
    Park, Yikyung
    Morton, Lindsay M.
    Hoover, Robert N.
    de Gonzalez, Amy Berrington
    [J]. JOURNAL OF UROLOGY, 2013, 189 (04): : E135 - E135
  • [32] Impact of PSA screening on mortality - PLCO Project Team (Prostate, Lung, Colorectal, Ovarian Cancer Screening Trial)
    Heidenreich, A.
    Nitschmann, S.
    [J]. INTERNIST, 2010, 51 (02): : 219 - 220
  • [33] Validation of an Algorithm for Classifying Interval Colorectal Cancer Occurrence: Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial
    Pabby, Ajay
    Weissfeld, Joel L.
    Pinsky, Paul F.
    Hayes, Richard B.
    Schoen, Robert E.
    [J]. GASTROINTESTINAL ENDOSCOPY, 2006, 63 (05) : AB220 - AB220
  • [34] Dietary phytoestrogen intake and lung cancer risk: an analysis of the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial
    Wang, Qian
    Ru, Meng
    Zhang, Yaning
    Kurbanova, Tamara
    Boffetta, Paolo
    [J]. CARCINOGENESIS, 2021, 42 (10) : 1250 - 1259
  • [35] Cumulative false-positives (FP) in the prostate, lung, colorectal, ovarian (PLCO) cancer screening trial
    Miller, J. H.
    Kramer, B. S.
    Kreimer, A. R.
    Prorok, P. C.
    Xu, J.
    Baker, S. G.
    Fagerstrom, R.
    Berg, C. D.
    Gohagan, J. K.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [36] Dietary fat intake and risk of pancreatic cancer in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial
    Arem, Hannah E.
    Mayne, Susan T.
    Sampson, Joshua
    Risch, Harvey
    Stolzenberg-Solomon, Rachael Z.
    [J]. CANCER RESEARCH, 2013, 73 (08)
  • [37] Inflammatory potential of diet and risk of pancreatic cancer in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial
    Zheng, Jiali
    Merchant, Anwar T.
    Wirth, Michael D.
    Zhang, Jiajia
    Antwi, Samuel O.
    Shoaibi, Azza
    Shivappa, Nitin
    Stolzenberg-Solomon, Rachael Z.
    Hebert, James R.
    Steck, Susan E.
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2018, 142 (12) : 2461 - 2470
  • [38] The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial of the National Cancer Institute: History, organization, and status
    Gohagan, JK
    Prorok, PC
    Hayes, RB
    Kramer, BS
    [J]. CONTROLLED CLINICAL TRIALS, 2000, 21 (06): : 251S - 272S
  • [39] Dietary patterns predict mortality in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (PLCO) cohort
    Tseng, Marilyn
    Graubard, Barry I.
    Ziegler, Regina
    [J]. FASEB JOURNAL, 2011, 25
  • [40] Recruitment strategies in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial: The first six years
    Simpson, NK
    Johnson, CC
    Ogden, SL
    Gamito, E
    Trocky, N
    McGuire, C
    Martin, J
    Barrow, S
    Lamerato, L
    Flickinger, LM
    Broski, KG
    Engelhard, D
    Hilke, C
    Bonk, J
    Gahagan, B
    Gren, LH
    Childs, J
    Lappe, K
    Fouad, M
    Thompson, J
    Sullivan, D
    [J]. CONTROLLED CLINICAL TRIALS, 2000, 21 (06): : 356S - 378S